NOV 11, 2015 06:00 AM PST

A Comprehensive Toxicology Screening Solution Targeted to Individual Needs

  • Director of Clinical Chemistry, Houston Methodist Hospital, Associate Professor, Pathology and Laboratory Medicine, Weill Cornell Medical College
      Dr. Ping Wang is currently the Medical Director of Clinical Chemistry at Houston Methodist Hospital and Associate Professor of Pathology and Laboratory Medicine at Weill Cornell Medical College. She is also Director of the ComACC-accredited Postdoctoral Fellowship Program at Houston Methodist Hospital. Dr. Wang was trained at Tsinghua University, University of Wisconsin-Madison and UCSF. She is board certified in Clinical Chemistry, Molecular Diagnostics and Toxicological Chemistry by American Board of Clinical Chemistry, for which she currently serves as Vice President and Chair of Examination Committee. She is a fellow of the National Academy of Clinical Biochemistry. She currently serves or had served on the boards of NACCCA, AACC LVDD division and TDM and Toxicology division. Dr. Wang has received many honors and awards including the Career Cornerstone Award, NACB Distinguished Abstract Award and AACC Outstanding Research Award. She has published over 60 peer-reviewed papers, abstracts and book chapters. Dr. Wang has over 10 years of experience directing and managing high complexity CLIA clinical laboratories, and is an expert in CLIA regulations, laboratory management to drive clinical efficiency, quality and outcome, clinical assay development, optimization and execution in a highly regulated environment. Besides clinical service and teaching, Dr. Wang's current research interests focus on translating novel research and start-up findings into clinical diagnostic tools. She is Principle Investigator of two NIH grants, and actively collaborates with major diagnostic companies as well as start-up ventures to develop next-generation diagnostic tools.


    Drugs of abuse toxicology testing by immunoassays is widely used clinically, but also known to be inadequate for many clinical indications. In this presentation, the speaker will outline different reasons for which the provider want clinical toxicology testing, and describe a comprehensive solution using both immunoassays and LC tandem mass spectrometry to target individual needs. The speaker will also discuss the performance details of the LC tandem mass spectrometry method. After completing this activity, the learner will be able to describe several clinical needs for toxicology testing. They will also be able to describe a comprehensive solution for clinical toxicology screening, targeted to these individual needs.

    Show Resources
    Loading Comments...